Murine infection models for vaccine development

References

• Okiro EA, Bitira D, Mbabazi G, Mpimbaza A, Alegana VA, Talisuna AO, et al. Increasing malaria hospital admissions in Uganda between 1999 and 2009. BMC Med 2011; 9:37; http://dx.doi.org/10.1186/1741-7015-9-37; PMID: 21486498
   PubMed Web of Science ®Google Scholar
• Roca-Feltrer A, Kwizombe CJ, Sanjoaquin MA, Sesay SSS, Faragher B, Harrison J, et al. Lack of decline in childhood malaria, Malawi, 2001-2010. Emerg Infect Dis 2012; 18:272 - 8; http://dx.doi.org/10.3201/eid1802.111008; PMID: 22305090
   PubMed Web of Science ®Google Scholar
• Murray CJL, Rosenfeld LC, Lim SS, Andrews KG, Foreman KJ, Haring D, et al. Global malaria mortality between 1980 and 2010: a systematic analysis. Lancet 2012; 379:413 - 31; http://dx.doi.org/10.1016/S0140-6736(12)60034-8; PMID: 22305225
   PubMed Web of Science ®Google Scholar
• Prudêncio M, Rodriguez A, Mota MM. The silent path to thousands of merozoites: the Plasmodium liver stage. Nat Rev Microbiol 2006; 4:849 - 56; http://dx.doi.org/10.1038/nrmicro1529; PMID: 17041632
   PubMed Web of Science ®Google Scholar
• Silvie O, Mota MM, Matuschewski K, Prudêncio M. Interactions of the malaria parasite and its mammalian host. Curr Opin Microbiol 2008; 11:352 - 9; http://dx.doi.org/10.1016/j.mib.2008.06.005; PMID: 18644249
   PubMed Web of Science ®Google Scholar
• Borrmann S, Matuschewski K. Targeting Plasmodium liver stages: better late than never. Trends Mol Med 2011; 17:527 - 36; http://dx.doi.org/10.1016/j.molmed.2011.05.008; PMID: 21737347
   PubMed Web of Science ®Google Scholar
• Hafalla JC, Silvie O, Matuschewski K. Cell biology and immunology of malaria. Immunol Rev 2011; 240:297 - 316; http://dx.doi.org/10.1111/j.1600-065X.2010.00988.x; PMID: 21349101
   PubMed Web of Science ®Google Scholar
• Hill AVS. Pre-erythrocytic malaria vaccines: towards greater efficacy. Nat Rev Immunol 2006; 6:21 - 32; http://dx.doi.org/10.1038/nri1746; PMID: 16493425
   PubMed Web of Science ®Google Scholar
• Haldar K, Murphy SC, Milner DA Jr., Taylor TE. Malaria: mechanisms of erythrocytic infection and pathological correlates of severe disease. Annu Rev Pathol 2007; 2:217 - 49; http://dx.doi.org/10.1146/annurev.pathol.2.010506.091913; PMID: 18039099
   PubMed Web of Science ®Google Scholar
• Maier AG, Cooke BM, Cowman AF, Tilley L. Malaria parasite proteins that remodel the host erythrocyte. Nat Rev Microbiol 2009; 7:341 - 54; http://dx.doi.org/10.1038/nrmicro2110; PMID: 19369950
   PubMed Web of Science ®Google Scholar
• Bouharoun-Tayoun H, Attanath P, Sabchareon A, Chongsuphajaisiddhi T, Druilhe P. Antibodies that protect humans against Plasmodium falciparum blood stages do not on their own inhibit parasite growth and invasion in vitro, but act in cooperation with monocytes. J Exp Med 1990; 172:1633 - 41; http://dx.doi.org/10.1084/jem.172.6.1633; PMID: 2258697
   PubMed Web of Science ®Google Scholar
• Fowkes FJI, Richards JS, Simpson JA, Beeson JG. The relationship between anti-merozoite antibodies and incidence of Plasmodium falciparum malaria: A systematic review and meta-analysis. PLoS Med 2010; 7:e1000218; http://dx.doi.org/10.1371/journal.pmed.1000218; PMID: 20098724
   PubMed Web of Science ®Google Scholar
• Good MF, Stanisic D, Xu H, Elliott S, Wykes M. The immunological challenge to developing a vaccine to the blood stages of malaria parasites. Immunol Rev 2004; 201:254 - 67; http://dx.doi.org/10.1111/j.0105-2896.2004.00178.x; PMID: 15361246
   PubMed Web of Science ®Google Scholar
• Talman AM, Domarle O, McKenzie FE, Ariey F, Robert V. Gametocytogenesis: the puberty of Plasmodium falciparum.. Malar J 2004; 3:24; http://dx.doi.org/10.1186/1475-2875-3-24; PMID: 15253774
   PubMed Web of Science ®Google Scholar
• Kooij TW, Matuschewski K. Triggers and tricks of Plasmodium sexual development. Curr Opin Microbiol 2007; 10:547 - 53; http://dx.doi.org/10.1016/j.mib.2007.09.015; PMID: 18006365
   PubMed Web of Science ®Google Scholar
• Kaslow DC, Quakyi IA, Syin C, Raum MG, Keister DB, Coligan JE, et al. A vaccine candidate from the sexual stage of human malaria that contains EGF-like domains. Nature 1988; 333:74 - 6; http://dx.doi.org/10.1038/333074a0; PMID: 3283563
   PubMed Web of Science ®Google Scholar
• Carter R. Transmission blocking malaria vaccines. Vaccine 2001; 19:2309 - 14; http://dx.doi.org/10.1016/S0264-410X(00)00521-1; PMID: 11257353
   PubMed Web of Science ®Google Scholar
• Nussenzweig RS, Vanderberg J, Most H, Orton C. Protective immunity produced by the injection of x-irradiated sporozoites of plasmodium berghei.. Nature 1967; 216:160 - 2; http://dx.doi.org/10.1038/216160a0; PMID: 6057225
   PubMed Web of Science ®Google Scholar
• Mueller AK, Labaied M, Kappe SHI, Matuschewski K. Genetically modified Plasmodium parasites as a protective experimental malaria vaccine. Nature 2005; 433:164 - 7; http://dx.doi.org/10.1038/nature03188; PMID: 15580261
   PubMed Web of Science ®Google Scholar
• Friesen J, Silvie O, Putrianti ED, Hafalla JCR, Matuschewski K, Borrmann S. Natural immunization against malaria: causal prophylaxis with antibiotics. Sci Transl Med 2010; 2:40ra49; http://dx.doi.org/10.1126/scitranslmed.3001058; PMID: 20630856
   PubMed Web of Science ®Google Scholar
• Matuschewski K. Hitting malaria before it hurts: attenuated Plasmodium liver stages. Cell Mol Life Sci 2007; 64:3007 - 11; http://dx.doi.org/10.1007/s00018-007-7263-z; PMID: 17876525
   PubMed Web of Science ®Google Scholar
• Matuschewski K, Hafalla JC, Borrmann S, Friesen J. Arrested Plasmodium liver stages as experimental anti-malaria vaccines. Hum Vaccin 2011; 7:Suppl 16 - 21; http://dx.doi.org/10.4161/hv.7.0.14557; PMID: 21266857
   PubMed Web of Science ®Google Scholar
• Holder AA, Freeman RR. Immunization against blood-stage rodent malaria using purified parasite antigens. Nature 1981; 294:361 - 4; http://dx.doi.org/10.1038/294361a0; PMID: 7312033
   PubMed Web of Science ®Google Scholar
• Ling IT, Ogun SA, Holder AA. Immunization against malaria with a recombinant protein. Parasite Immunol 1994; 16:63 - 7; http://dx.doi.org/10.1111/j.1365-3024.1994.tb00324.x; PMID: 8015856
   PubMed Web of Science ®Google Scholar
• Quakyi IA, Carter R, Rener J, Kumar N, Good MF, Miller LH. The 230-kDa gamete surface protein of Plasmodium falciparum is also a target for transmission-blocking antibodies. J Immunol 1987; 139:4213 - 7; PMID: 2447164
   PubMed Web of Science ®Google Scholar
• Barr PJ, Green KM, Gibson HL, Bathurst IC, Quakyi IA, Kaslow DC. Recombinant Pfs25 protein of Plasmodium falciparum elicits malaria transmission-blocking immunity in experimental animals. J Exp Med 1991; 174:1203 - 8; http://dx.doi.org/10.1084/jem.174.5.1203; PMID: 1940798
   PubMed Web of Science ®Google Scholar
• Langhorne J, Ndungu FM, Sponaas AM, Marsh K. Immunity to malaria: more questions than answers. Nat Immunol 2008; 9:725 - 32; http://dx.doi.org/10.1038/ni.f.205; PMID: 18563083
   PubMed Web of Science ®Google Scholar
• Struik SS, Riley EM. Does malaria suffer from lack of memory?. Immunol Rev 2004; 201:268 - 90; http://dx.doi.org/10.1111/j.0105-2896.2004.00181.x; PMID: 15361247
   PubMed Web of Science ®Google Scholar
• Offeddu V, Thathy V, Marsh K, Matuschewski K. Naturally acquired immune responses against Plasmodium falciparum sporozoites and liver infection. Int J Parasitol 2012; 42:535 - 48; http://dx.doi.org/10.1016/j.ijpara.2012.03.011; PMID: 22561398
   PubMed Web of Science ®Google Scholar
• Perkins SL, Schall JJ. A molecular phylogeny of malarial parasites recovered from cytochrome b gene sequences. J Parasitol 2002; 88:972 - 8; PMID: 12435139
   PubMed Web of Science ®Google Scholar
• Vincke JH, Lips M. Un noveau Plasmodium d’un Rongeur suvage du Congo Plasmodium berghei n.sp.. Ann Soc Belg Med Trop 1948; 28:97 - 104
   PubMedGoogle Scholar
• Kooij TW, Carlton JM, Bidwell SL, Hall N, Ramesar J, Janse CJ, et al. A Plasmodium whole-genome synteny map: indels and synteny breakpoints as foci for species-specific genes. PLoS Pathog 2005; 1:e44; http://dx.doi.org/10.1371/journal.ppat.0010044; PMID: 16389297
   PubMedGoogle Scholar
• Janse CJ, Kroeze H, van Wigcheren A, Mededovic S, Fonager J, Franke-Fayard B, et al. A genotype and phenotype database of genetically modified malaria-parasites. Trends Parasitol 2011; 27:31 - 9; http://dx.doi.org/10.1016/j.pt.2010.06.016; PMID: 20663715
   PubMed Web of Science ®Google Scholar
• Austin CP, Battey JF, Bradley A, Bucan M, Capecchi M, Collins FS, et al. The knockout mouse project. Nat Genet 2004; 36:921 - 4; http://dx.doi.org/10.1038/ng0904-921; PMID: 15340423
   PubMed Web of Science ®Google Scholar
• Ngonseu E, Chatterjee S, Wery M. Blocked hepatic-stage parasites and decreased susceptibility to Plasmodium berghei infections in BALB/c mice. Parasitology 1998; 117:419 - 23; http://dx.doi.org/10.1017/S0031182098003333; PMID: 9836306
   PubMed Web of Science ®Google Scholar
• Doolan DL, Hoffman SL. The complexity of protective immunity against liver-stage malaria. J Immunol 2000; 165:1453 - 62; PMID: 10903750
   PubMed Web of Science ®Google Scholar
• de Souza JB, Hafalla JCR, Riley EM, Couper KN. Cerebral malaria: why experimental murine models are required to understand the pathogenesis of disease. Parasitology 2010; 137:755 - 72; http://dx.doi.org/10.1017/S0031182009991715; PMID: 20028608
   PubMed Web of Science ®Google Scholar
• Lovegrove FE, Gharib SA, Peña-Castillo L, Patel SN, Ruzinski JT, Hughes TR, et al. Parasite burden and CD36-mediated sequestration are determinants of acute lung injury in an experimental malaria model. PLoS Pathog 2008; 4:e1000068; http://dx.doi.org/10.1371/journal.ppat.1000068; PMID: 18483551
   PubMedGoogle Scholar
• Lamikanra AA, Brown D, Potocnik A, Casals-Pascual C, Langhorne J, Roberts DJ. Malarial anemia: of mice and men. Blood 2007; 110:18 - 28; http://dx.doi.org/10.1182/blood-2006-09-018069; PMID: 17341664
   PubMed Web of Science ®Google Scholar
• Killick-Kendrick R. Parasitic protozoa of the blood of rodents: a revision of Plasmodium berghei.. Parasitology 1974; 69:225 - 37; http://dx.doi.org/10.1017/S0031182000048071; PMID: 4214369
   PubMed Web of Science ®Google Scholar
• Weiss WR, Good MF, Hollingdale MR, Miller LH, Berzofsky JA. Genetic control of immunity to Plasmodium yoelii sporozoites. J Immunol 1989; 143:4263 - 6; PMID: 2512354
   PubMed Web of Science ®Google Scholar
• Khusmith S, Charoenvit Y, Kumar S, Sedegah M, Beaudoin RL, Hoffman SL. Protection against malaria by vaccination with sporozoite surface protein 2 plus CS protein. Science 1991; 252:715 - 8; http://dx.doi.org/10.1126/science.1827210; PMID: 1827210
   PubMed Web of Science ®Google Scholar
• Stephens R, Culleton RL, Lamb TJ. The contribution of Plasmodium chabaudi to our understanding of malaria. Trends Parasitol 2012; 28:73 - 82; http://dx.doi.org/10.1016/j.pt.2011.10.006; PMID: 22100995
   PubMed Web of Science ®Google Scholar
• Perlmann H, Kumar S, Vinetz JM, Kullberg M, Miller LH, Perlmann P. Cellular mechanisms in the immune response to malaria in Plasmodium vinckei-infected mice. Infect Immun 1995; 63:3987 - 93; PMID: 12471098
   PubMed Web of Science ®Google Scholar
• Persson C, Oliveira GA, Sultan AA, Bhanot P, Nussenzweig V, Nardin E. Cutting edge: a new tool to evaluate human pre-erythrocytic malaria vaccines: rodent parasites bearing a hybrid Plasmodium falciparum circumsporozoite protein. J Immunol 2002; 169:6681 - 5; PMID: 7558309
   PubMed Web of Science ®Google Scholar
• Dorner M, Horwitz JA, Robbins JB, Barry WT, Feng Q, Mu K, et al. A genetically humanized mouse model for hepatitis C virus infection. Nature 2011; 474:208 - 11; http://dx.doi.org/10.1038/nature10168; PMID: 21654804
   PubMed Web of Science ®Google Scholar
• Arnold L, Tyagi RK, Meija P, Swetman C, Gleeson J, Pérignon JL, et al. Further improvements of the P. falciparum humanized mouse model. PLoS One 2011; 6:e18045; http://dx.doi.org/10.1371/journal.pone.0018045; PMID: 21483851
   PubMed Web of Science ®Google Scholar
• Patarroyo ME, Romero P, Torres ML, Clavijo P, Moreno A, Martínez A, et al. Induction of protective immunity against experimental infection with malaria using synthetic peptides. Nature 1987; 328:629 - 32; http://dx.doi.org/10.1038/328629a0; PMID: 3302727
   PubMed Web of Science ®Google Scholar
• Patarroyo ME, Amador R, Clavijo P, Moreno A, Guzman F, Romero P, et al. A synthetic vaccine protects humans against challenge with asexual blood stages of Plasmodium falciparum malaria. Nature 1988; 332:158 - 61; http://dx.doi.org/10.1038/332158a0; PMID: 2450281
   PubMed Web of Science ®Google Scholar
• Valero MV, Amador LR, Galindo C, Figueroa J, Bello MS, Murillo LA, et al. Vaccination with SPf66, a chemically synthesised vaccine, against Plasmodium falciparum malaria in Colombia. Lancet 1993; 341:705 - 10; http://dx.doi.org/10.1016/0140-6736(93)90483-W; PMID: 8095622
   PubMed Web of Science ®Google Scholar
• Alonso PL, Smith T, Schellenberg JR, Masanja H, Mwankusye S, Urassa H, et al. Randomised trial of efficacy of SPf66 vaccine against Plasmodium falciparum malaria in children in southern Tanzania. Lancet 1994; 344:1175 - 81; http://dx.doi.org/10.1016/S0140-6736(94)90505-3; PMID: 7934537
   PubMed Web of Science ®Google Scholar
• Alonso PL, Smith TA, Armstrong-Schellenberg JRM, Kitua AY, Masanja H, Hayes R, et al. Duration of protection and age-dependence of the effects of the SPf66 malaria vaccine in African children exposed to intense transmission of Plasmodium falciparum.. J Infect Dis 1996; 174:367 - 72; http://dx.doi.org/10.1093/infdis/174.2.367; PMID: 8699068
   PubMed Web of Science ®Google Scholar
• D’Alessandro U, Leach A, Drakeley CJ, Bennett S, Olaleye BO, Fegan GW, et al. Efficacy trial of malaria vaccine SPf66 in Gambian infants. Lancet 1995; 346:462 - 7; http://dx.doi.org/10.1016/S0140-6736(95)91321-1; PMID: 7637479
   PubMed Web of Science ®Google Scholar
• Nosten F, Luxemburger C, Kyle DE, Ballou WR, Wittes J, Wah E, et al. Randomised double-blind placebo-controlled trial of SPf66 malaria vaccine in children in northwestern Thailand. Shoklo SPf66 Malaria Vaccine Trial Group. Lancet 1996; 348:701 - 7; http://dx.doi.org/10.1016/S0140-6736(96)04465-0; PMID: 8806288
   PubMed Web of Science ®Google Scholar
• Ballou WR. The development of the RTS,S malaria vaccine candidate: challenges and lessons. Parasite Immunol 2009; 31:492 - 500; http://dx.doi.org/10.1111/j.1365-3024.2009.01143.x; PMID: 19691554
   PubMed Web of Science ®Google Scholar
• Cohen J, Nussenzweig V, Nussenzweig R, Vekemans J, Leach A. From the circumsporozoite protein to the RTS, S/AS candidate vaccine. Hum Vaccin 2010; 6:90 - 6; http://dx.doi.org/10.4161/hv.6.1.9677; PMID: 19806009
   PubMed Web of Science ®Google Scholar
• Stoute JA, Slaoui M, Heppner DG, Momin P, Kester KE, Desmons P, et al. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group. N Engl J Med 1997; 336:86 - 91; http://dx.doi.org/10.1056/NEJM199701093360202; PMID: 8988885
   PubMed Web of Science ®Google Scholar
• Kester KE, McKinney DA, Tornieporth N, Ockenhouse CF, Heppner DG, Hall T, et al, RTS,S Malaria Vaccine Evaluation Group. Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria. J Infect Dis 2001; 183:640 - 7; http://dx.doi.org/10.1086/318534; PMID: 11170991
   PubMed Web of Science ®Google Scholar
• Kester KE, McKinney DA, Tornieporth N, Ockenhouse CF, Heppner DG Jr., Hall T, et al, RTS,S Malaria Vaccine Evaluation Group. A phase I/IIa safety, immunogenicity, and efficacy bridging randomized study of a two-dose regimen of liquid and lyophilized formulations of the candidate malaria vaccine RTS,S/AS02A in malaria-naïve adults. Vaccine 2007; 25:5359 - 66; http://dx.doi.org/10.1016/j.vaccine.2007.05.005; PMID: 17574311
   PubMed Web of Science ®Google Scholar
• Bojang KA, Milligan PJM, Pinder M, Vigneron L, Alloueche A, Kester KE, et al, RTS, S Malaria Vaccine Trial Team. Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. Lancet 2001; 358:1927 - 34; http://dx.doi.org/10.1016/S0140-6736(01)06957-4; PMID: 11747915
   PubMed Web of Science ®Google Scholar
• Alonso PL, Sacarlal J, Aponte JJ, Leach A, Macete E, Milman J, et al. Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet 2004; 364:1411 - 20; http://dx.doi.org/10.1016/S0140-6736(04)17223-1; PMID: 15488216
   PubMed Web of Science ®Google Scholar
• Alonso PL, Sacarlal J, Aponte JJ, Leach A, Macete E, Aide P, et al. Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial. Lancet 2005; 366:2012 - 8; http://dx.doi.org/10.1016/S0140-6736(05)67669-6; PMID: 16338450
   PubMed Web of Science ®Google Scholar
• Bejon P, Lusingu J, Olotu A, Leach A, Lievens M, Vekemans J, et al. Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age. N Engl J Med 2008; 359:2521 - 32; http://dx.doi.org/10.1056/NEJMoa0807381; PMID: 19064627
   PubMed Web of Science ®Google Scholar
• Agnandji ST, Lell B, Soulanoudjingar SS, Fernandes JF, Abossolo BP, Conzelmann C, et al, RTS,S Clinical Trials Partnership. First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. N Engl J Med 2011; 365:1863 - 75; http://dx.doi.org/10.1056/NEJMoa1102287; PMID: 22007715
   PubMed Web of Science ®Google Scholar
• Agnandji ST, Lell B, Fernandes JF, Abossolo BP, Methogo BGNO, Kawende AL, et al. A Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Infants. N Engl J Med 2012; 367:2284 - 95; http://dx.doi.org/10.1056/NEJMoa1208394; PMID: 23136909
   PubMed Web of Science ®Google Scholar
• Lal AA, de la Cruz VF, Good MF, Weiss WR, Lunde M, Maloy WL, et al. In vivo testing of subunit vaccines against malaria sporozoites using a rodent system. Proc Natl Acad Sci U S A 1987; 84:8647 - 51; http://dx.doi.org/10.1073/pnas.84.23.8647; PMID: 3479809
   PubMed Web of Science ®Google Scholar
• Przysiecki C, Lucas B, Mitchell R, Carapau D, Wen Z, Xu H, et al. Sporozoite neutralizing antibodies elicited in mice and rhesus macaques immunized with a Plasmodium falciparum repeat peptide conjugated to meningococcal outer membrane protein complex. Frontiers Cell Infect Microbiol 2012; 2:146; http://dx.doi.org/10.3389/fcimb.2012.00146; PMID: 23226683
   PubMed Web of Science ®Google Scholar
• Miller JD, van der Most RG, Akondy RS, Glidewell JT, Albott S, Masopust D, et al. Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines. Immunity 2008; 28:710 - 22; http://dx.doi.org/10.1016/j.immuni.2008.02.020; PMID: 18468462
   PubMed Web of Science ®Google Scholar
• Nussenzweig RS, Vanderberg J, Most H, Orton C. Protective immunity produced by the injection of x-irradiated sporozoites of plasmodium berghei.. Nature 1967; 216:160 - 2; http://dx.doi.org/10.1038/216160a0; PMID: 6057225
   PubMed Web of Science ®Google Scholar
• Nussenzweig RS, Vanderberg JP, Most H, Orton C. Specificity of protective immunity produced by x-irradiated Plasmodium berghei sporozoites. Nature 1969; 222:488 - 9; http://dx.doi.org/10.1038/222488a0; PMID: 5768632
   PubMed Web of Science ®Google Scholar
• Gwadz RW, Cochrane AH, Nussenzweig V, Nussenzweig RS. Preliminary studies on vaccination of rhesus monkeys with irradiated sporozoites of Plasmodium knowlesi and characterization of surface antigens of these parasites. Bull World Health Organ 1979; 57:Suppl 1 165 - 73; PMID: 120766
   PubMedGoogle Scholar
• Clyde DF, Most H, McCarthy VC, Vanderberg JP. Immunization of man against sporozite-induced falciparum malaria. Am J Med Sci 1973; 266:169 - 77; http://dx.doi.org/10.1097/00000441-197309000-00002; PMID: 4583408
   PubMed Web of Science ®Google Scholar
• Hoffman SL, Goh LM, Luke TC, Schneider I, Le TP, Doolan DL, et al. Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. J Infect Dis 2002; 185:1155 - 64; http://dx.doi.org/10.1086/339409; PMID: 11930326
   PubMed Web of Science ®Google Scholar
• Epstein JE, Rao S, Williams F, Freilich D, Luke T, Sedegah M, et al. Safety and clinical outcome of experimental challenge of human volunteers with Plasmodium falciparum-infected mosquitoes: an update. J Infect Dis 2007; 196:145 - 54; http://dx.doi.org/10.1086/518510; PMID: 17538895
   PubMed Web of Science ®Google Scholar
• Hoffman SL, Billingsley PF, James E, Richman A, Loyevsky M, Li T, et al. Development of a metabolically active, non-replicating sporozoite vaccine to prevent Plasmodium falciparum malaria. Hum Vaccin 2010; 6:97 - 106; http://dx.doi.org/10.4161/hv.6.1.10396; PMID: 19946222
   PubMed Web of Science ®Google Scholar
• Epstein JE, Tewari K, Lyke KE, Sim BK, Billingsley PF, Laurens MB, et al. Live attenuated malaria vaccine designed to protect through hepatic CD8⁺ T cell immunity. Science 2011; 334:475 - 80; http://dx.doi.org/10.1126/science.1211548; PMID: 21903775
   PubMed Web of Science ®Google Scholar
• Beaudoin RL, Strome CPA, Mitchell F, Tubergen TA. Plasmodium berghei: immunization of mice against the ANKA strain using the unaltered sporozoite as an antigen. Exp Parasitol 1977; 42:1 - 5; http://dx.doi.org/10.1016/0014-4894(77)90054-6; PMID: 324783
   PubMed Web of Science ®Google Scholar
• Orjih AU, Cochrane AH, Nussenzweig RS. Comparative studies on the immunogenicity of infective and attenuated sporozoites of Plasmodium berghei.. Trans R Soc Trop Med Hyg 1982; 76:57 - 61; http://dx.doi.org/10.1016/0035-9203(82)90019-0; PMID: 7043807
   PubMed Web of Science ®Google Scholar
• Belnoue E, Costa FTM, Frankenberg T, Vigário AM, Voza T, Leroy N, et al. Protective T cell immunity against malaria liver stage after vaccination with live sporozoites under chloroquine treatment. J Immunol 2004; 172:2487 - 95; PMID: 14764721
   PubMed Web of Science ®Google Scholar
• Roestenberg M, McCall M, Hopman J, Wiersma J, Luty AJ, van Gemert GJ, et al. Protection against a malaria challenge by sporozoite inoculation. N Engl J Med 2009; 361:468 - 77; http://dx.doi.org/10.1056/NEJMoa0805832; PMID: 19641203
   PubMed Web of Science ®Google Scholar
• Roestenberg M, Teirlinck AC, McCall MB, Teelen K, Makamdop KN, Wiersma J, et al. Long-term protection against malaria after experimental sporozoite inoculation: an open-label follow-up study. Lancet 2011; 377:1770 - 6; http://dx.doi.org/10.1016/S0140-6736(11)60360-7; PMID: 21514658
   PubMed Web of Science ®Google Scholar
• Putrianti ED, Silvie O, Kordes M, Borrmann S, Matuschewski K. Vaccine-like immunity against malaria by repeated causal-prophylactic treatment of liver-stage Plasmodium parasites. J Infect Dis 2009; 199:899 - 903; http://dx.doi.org/10.1086/597121; PMID: 19434915
   PubMed Web of Science ®Google Scholar
• Friesen J, Matuschewski K. Comparative efficacy of pre-erythrocytic whole organism vaccine strategies against the malaria parasite. Vaccine 2011; 29:7002 - 8; http://dx.doi.org/10.1126/scitranslmed.3001058; PMID: 20630856
   PubMed Web of Science ®Google Scholar
• Borrmann S, Matuschewski K. Protective immunity against malaria by ‘natural immunization’: a question of dose, parasite diversity, or both?. Curr Opin Immunol 2011; 23:500 - 8; http://dx.doi.org/10.1016/j.coi.2011.05.009; PMID: 21719266
   PubMed Web of Science ®Google Scholar
• Silvie O, Goetz K, Matuschewski K. A sporozoite asparagine-rich protein controls initiation of Plasmodium liver stage development. PLoS Pathog 2008; 4:e1000086; http://dx.doi.org/10.1371/journal.ppat.1000086; PMID: 18551171
   PubMed Web of Science ®Google Scholar
• Haussig JM, Matuschewski K, Kooij TW. Inactivation of a Plasmodium apicoplast protein attenuates formation of liver merozoites. Mol Microbiol 2011; 81:1511 - 25; http://dx.doi.org/10.1111/j.1365-2958.2011.07787.x; PMID: 21848587
   PubMed Web of Science ®Google Scholar
• VanBuskirk KM, O’Neill MT, De La Vega P, Maier AG, Krzych U, Williams J, et al. Preerythrocytic, live-attenuated Plasmodium falciparum vaccine candidates by design. Proc Natl Acad Sci U S A 2009; 106:13004 - 9; http://dx.doi.org/10.1073/pnas.0906387106; PMID: 19625622
   PubMed Web of Science ®Google Scholar
• Annoura T, Ploemen IH, van Schaijk BC, Sajid M, Vos MW, van Gemert GJ, et al. Assessing the adequacy of attenuation of genetically modified malaria parasite vaccine candidates. Vaccine 2012; 30:2662 - 70; http://dx.doi.org/10.1016/j.vaccine.2012.02.010; PMID: 22342550
   PubMed Web of Science ®Google Scholar